Phathom Pharmaceuticals (NASDAQ: PHAT) reported quarterly earnings of $0.00 per share which beat the analyst consensus estimate of $(0.25) by 100 percent. This is a 100 percent increase over losses of $(0.79) per share from the same period last year. The company reported quarterly sales of $74.300 million which beat the analyst consensus estimate of $72.789 million by 2.08 percent. This is a 88.09 percent increase over sales of $39.503 million the same period last year.